Australia's most trusted
source of pharma news
Friday, 17 May 2024
Posted 29 April 2024 AM
Most companies that made a new PBS listing submission to the PBAC's hefty March meeting have come out with a win with only six of the 42 submissions not recommended.
In the final meeting presided over by PBAC Chair Professor Andrew Wilson, ahead of his retirement, the clear winner was AstraZeneca, which had all four of its new listing submissions recommended.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.